A phase II, open label, single arm study to assess the efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy(WJOG8815L) - A phase II study to assess the efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer with T790M mutation detected and quid biopsy and with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy(WJOG8815L)

Clinical trial coordinating committee for WJOG8815L investigator-initiated multicenter clinical trial0 个研究点目标入组 60 人开始时间: 2016年4月26日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1.Involvement in the planning and/or conduct of the study 2.Treatment with any of the following: - Treatment with an EGFR-TKI within 8 days or approximately 5x half-life of the first dose of study treatment - Any cytotoxic chemotherapy within 14 days of the first dose of study treatment - Or previous treatment with a 3rd generation EGFR TKIs - Major surgery within 4 weeks of the first dose of study treatment - Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study treatment - Patients currently receiving medications known to be potent inhibitors or inducers of cytochrome P4503A4(CYP3A4) - Treatment with an investigational drug within approximately five half-lives of the compound 3.Any unresolved toxicities from prior therapy greater than CTCAE grade 2 (with the exception of alopecia and G2, prior platinum-therapy related neuropathy) 4.Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment. 5.Any evidence of severe or difficult-to-control systemic diseases(difficult-to-control hypertension and active bleeding diatheses, hepatitis B, hepatitis C and HIV etc.) 6.Refractory nausea and vomiting, chronic gastrointestinal diseases or inability to swallow the formulated product or previous bowel resection, etc. that may significantly affect adequate absorption of investigational product 7.Patients with resting corrected QT interval more than 470 msec, any clinically important abnormalities in resting ECG, or any risk factors of QTc prolongation or arrhythmic events 8.Past medical history of interstitial lung disease(ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD 9.Inadequate bone marrow reserve or organ function as demonstrated by any of the laboratory values 10.Women who are breast-feeding 11.History of malignant tumor

研究者

发起方

Clinical trial coordinating committee for WJOG8815L investigator-initiated multicenter clinical trial

相似试验

进行中（未招募）

1 期

A study to assess the effectiveness of the drug lucitanib in lung cancer patientsFGFR1-amplified squamous non-small cell lung cancer (NSCLC)MedDRA version: 16.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-003874-29-ITEOS S.p.A.40

进行中（未招募）

1 期

A study to assess the effectiveness of the drug lucitanib in lung cancer patients

EUCTR2013-003874-29-ESEOS S.p.A.18

进行中（未招募）

1 期

_Patients with progressing metastatic breast cancer pretreated with at least one line of chemotherapy at the metastatic setting.MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864

EUCTR2015-000580-14-FRICANCER40

进行中（未招募）

1 期

A study to assess the effectiveness of the drug lucitanib in lung cancer patientsAdvanced/metastatic lung cancer and FGF, VEGF, or PDGF-related genetic alterationsMedDRA version: 18.1Level: PTClassification code 10050017Term: Lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-003874-29-DEClovis Oncology Italy s.r.l.40

已完成

2 期

Efficacy and safety of Decapeptyl® SR by subcutaneous injection in patients with a diagnosis of prostate cancerTopic: Renal and Urogenital, National Cancer Research NetworkSubtopic: Renal and Urogenital (all Subtopics)Disease: UrogenitalCancerProstate Cancer

ISRCTN02365168niversity Hospitals Bristol NHS Foundation Trust (UK)50